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Background: Epithelial to mesenchymal transition (EMT) is a process in which epithelial cells lose polarity and
cell-to-cell contacts and acquire the migratory and invasive abilities of mesenchymal cells. These abilities are
thought to be prerequisites for the establishment of endometriotic lesions. A hallmark of EMT is the functional
loss of E-cadherin (CDH1) expression in epithelial cells. TWIST1, a transcription factor that represses E-cadherin
transcription, is among the EMT inducers. SNAIL, a zinc-finger transcription factor, and its close relative SLUG have
similar properties to TWIST1 and are thus also EMT inducers. MYC, which is upregulated by estrogens in the uterus
by an estrogen response cis-acting element (ERE) in its promoter, is associated with proliferation in endometriosis.
The role of EMT and proliferation in the pathogenesis of endometriosis was evaluated by analyzing TWIST1, CDH1
and MYC expression.
Methods: CDH1, TWIST1, SNAIL and SLUG mRNA expression was analyzed by qRT-PCR from 47 controls and 74 patients
with endometriosis. Approximately 42 ectopic and 62 eutopic endometrial tissues, of which 30 were matched samples,
were collected during the same surgical procedure. We evaluated TWIST1 and MYC protein expression by
immunohistochemistry (IHC) in the epithelial and stromal tissue of 69 eutopic and 90 ectopic endometrium
samples, of which 49 matched samples were analyzed from the same patient. Concordant expression of TWIST1/
SNAIL/SLUG and CDH1 but also of TWIST1 and MYC was analyzed.
Results: We found that TWIST1, SNAIL and SLUG are overexpressed (p < 0.001, p = 0.016 and p < 0.001) in
endometriosis, while CDH1 expression was concordantly reduced in these samples (p < 0.001). Similar to TWIST1,
the epithelial expression of MYC was also significantly enhanced in ectopic endometrium compared to eutopic
tissues (p = 0.008). We found exclusive expression of either TWIST1 or MYC in the same samples (p = 0.003).
Conclusions: Epithelial TWIST1 is overexpressed in endometriosis and may contribute to the formation of endometriotic
lesions by inducing epithelial to mesenchymal transition, as CDH1 was reduced in ectopic lesions. We found exclusive
expression of either TWIST1 or MYC in the same samples, indicating that EMT and proliferation contribute independently
of each other to the formation of endometriotic lesions.
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Endometriosis is a benign gynecological disease charac-
terized by the presence of functional endometrial glands
and stroma outside the uterine cavity [1]. The precise
etiology of endometriosis is unclear. One of the more
widely accepted hypotheses is that endometriosis origi-
nates from the retrograde menstruation of endometrial
cells that implant on peritoneal surfaces [2]. Although
retrograde menstruation can be observed in many
women, only a minority develop endometriosis. The
success of the ectopic implantation seems to be
dependent on several factors, including changes enab-
ling endometrial cell migration, adhesion and invasive
growth, as well as changes in anti-apoptotic signaling,
angiogenesis and inflammatory response [3, 1, 4]. Epi-
thelial to mesenchymal transition (EMT) is a process
whereby epithelial cells lose polarity and cell-to-cell
contacts and acquire the migratory and invasive abilities
of mesenchymal cells [5]. These abilities might be prereq-
uisites for the establishment of endometriotic lesions.
A hallmark of EMT is the functional loss of E-cadherin
expression in epithelial cells. For endometriosis, studies on
E-cadherin expression have led to contradictory results.
While some studies reported a reduction of E-cadherin ex-
pression in endometriosis compared with the endometrium
[6–9], others found no difference in E-cadherin expression
in endometriosis compared with the endometrium [10–14].
Previous studies demonstrated that E-cadherin-negative
epithelial cells were increased in peritoneal endometri-
osis compared with eutopic endometrium and that
in vitro, E-cadherin-negative, N-cadherin-positive endo-
metriotic epithelial cells showed invasive growth [15, 16].
Loss of E-cadherin expression together with a cadherin
switch, in which E-cadherin is replaced by the expression
of mesenchymal cadherins such as N-cadherin, is an
important feature of EMT [5].
TWIST1, a highly conserved basic helix-loop-helix
(bHLH) transcription factor that represses E-cadherin
(CDH1) transcription, represents an EMT inducer and
has been convincingly associated with tumor progres-
sion and the metastatic process [17–19].
SNAIL, a zinc-finger transcription factor, and its close
relative SLUG have similar properties to TWIST1 and
thus belong to the EMT inducers [14].
Factors that facilitate the survival and proliferation of
misplaced endometrial cells may also contribute to the
development of endometriosis. In endometriosis, epithe-
lial and stromal cells show a lower number of apoptotic
cells than in patients without endometriosis [20–22]. It
has been hypothesized that the expression of the anti-
apoptotic factor BCL-2 and the reduction of the pro-
apoptotic factor BAX in endometriosis lesions allows for
the survival of the tissue in ectopic sites [23, 24, 21, 22].
Increased expression of genes such as MYC, Cyclin D1,and Ki67 was shown to be upregulated in ectopic tissues,
suggesting that lesions exhibit a higher proliferation rate
[25, 26, 23, 27, 28]. Several studies investigating MYC ex-
pression in endometriosis observed increased MYC mRNA
and protein expression in ectopic and eutopic endomet-
rium from endometriosis patients [26, 29–31, 25].
Using qRT-PCR and immunohistochemistry (IHC), we
analyzed the expression, localization and correlation of
CDH1 and TWIST1, CDH1 and SNAIL, CDH1 and SLUG,
and TWIST1 and MYC in more than 100 ectopic and euto-
pic endometrial tissues from the proliferative and secretory
endometrium of women with endometriosis and in matched
tissue samples from the same patients. At present, the con-
current expression of TWIST1 and MYC in the same sam-
ple and in paired analysis of eutopic and ectopic tissues of
the same patient has never been evaluated.
Methods
Patients and tissue samples
Samples were collected between 2010 and 2014 and
were analyzed under protocols approved by the institu-
tional review board of the Medical University of Vienna
(6th July 2010, reference number 545/2010). Signed in-
formed consent was obtained from each participant of
this study.
For qRT-PCR, tissue samples were obtained from 121
premenopausal women (mean age 32.3 ± 5.9 years) who
underwent laparoscopic surgery at the certified Endomet-
riosis Centre at the university-affiliated General Hospital
of Vienna between 2010 and 2014 due to the suspicion of
endometriosis with or without infertility. The 121 cases
consisted of 74 patients with endometriosis and 47 control
patients who also underwent hysteroscopy, including dila-
tion and curettage, due to unexplained infertility. Among
the 74 cases with endometriosis, we obtained matched
samples of ectopic and eutopic endometrium in 30 cases,
exclusively eutopic endometrium in 12 cases, and exclu-
sively ectopic endometrium in 32 cases. The matched
sample tissues were collected during the same surgical
procedure. Endometriosis was diagnosed histologically in
62 patients and by visual inspection in 12 patients. Staging
was performed according to the revised American Fertility
Society (rAFS) classification guidelines (I, n = 10; II, n = 9;
III, n = 25; IV, n = 30) [32]. Patients with malignant dis-
eases of the ovaries or the endometrium were excluded.
Ectopic lesions consisted of ovarian lesions (n = 40), peri-
toneal lesions (n = 13), and deep infiltrating lesions (n = 9).
Characteristics of the study populations are provided in
Additional file 1: Table S1.
For IHC, tissue samples were collected under the same
conditions as for the qRT-PCR samples. The 160 cases con-
sisted of 110 patients with endometriosis and 50 control pa-
tients who underwent dilation and curettage for benign
indications. Among the 110 cases with endometriosis, we
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rium in 49 cases, exclusively eutopic endometrium in 20
cases, and exclusively ectopic endometrium in 41 cases. Sta-
ging was performed according to the revised American Fer-
tility Society (rAFS) classification guidelines (I, n = 17; II, n
= 23; III, n = 22; IV, n = 25) [32]. Characteristics of the study
populations are provided in Additional file 2: Table S2.
Quantitative Real-Time PCR (qRT-PCR)
Briefly, total RNA was isolated from fresh frozen tissues
with the Absolutely RNA miRNA Kit (Agilent) and
reverse-transcribed with the SuperScript First-Strand Kit
(Invitrogen) according to the manufacturers’ instruc-
tions. Each sample was analyzed by real-time PCR on an
Applied Biosystems 7500 fast instrument, using gene-
specific primers and fluorescent probes obtained from
Applied Biosystems: CDH1, Hs_01023894_m1; TWIST1,
Hs_01675818_m1; SNAIL, Hs_00195591_m1; SLUG,
Hs_00950344_m1; GAPDH, Hs_99999905_m1 (control),
and ACTB (control), Hs_99999903_m1. The mRNA
levels of CDH1, TWIST1, SNAIL and SLUG were nor-
malized to those of ACTB and GAPDH in each sample
by subtracting the mean Ct (threshold cycle) values of
the controls from the Ct value of CDH1, TWIST1,
SNAIL and SLUG as described previously [33]. For bin-
ary analysis, the cutoff was set at 0.162 for CDH1 ex-
pression, at 0.031 for TWIST1 expression, at 0.0075 for
SNAIL expression and at 0.156 for SLUG expression.
Immunohistochemistry (IHC)
TWIST1
Immunohistochemical staining was performed on forma-
lin-fixed, paraffin-embedded tissues. Three-micrometer-
thick sections were cut and placed on glass slides. Heat
antigen retrieval was performed in 10 mM Sodium Citrate
Buffer pH6. Nonspecific background staining was blocked
by incubation in H2O2 and with Ultra V Block (Thermo
Scientific, Ultra Vision LP Kit, TL-060-HL) according to the
protocol. The rabbit polyclonal IgG to humanTWIST
amino acids 12–27 (Abcam, ab50581) was applied at a dilu-
tion of 1:1200 with Antibody Diluent with Background
Reducing Components (Dako, S3022) and incubated over-
night at 4 °C. The Ultra Vision LP Kit was used according
to the protocol (Thermo Scientific, Ultra Vision LP Kit,
TL-060-HL). Finally, all slides were incubated with
DAB-Substrate (Dako, K346811) and counterstained in
hematoxylin before they were dehydrated and mounted.
MYC
MYC IHC was performed with a professional staining sys-
tem (AutostainerLink48, DAKO, Glostrup, Denmark) at
the Department of Pathology in the Wilhelminen Hos-
pital. Briefly, antigen retrieval was performed by boiling
the slides in EnVision FLEX Target Retrieval Solution athigh pH (Dako Kit, K8000) for 15 min at 97 °C. The block-
ing procedure was performed according to the protocol
(Dako, K8000). The rabbit monoclonal IgG to human c-
MYC [Y69] (Biocare, CME415AK, CK) was applied at a
dilution of 1:100 with Renoir Red Diluent (Biocare) and in-
cubated for 20 min at room temperature. The slides were
incubated with polymer according to the protocol (Dako,
K8000). Finally, all slides were incubated with DAB-
Substrate (Dako, K8000) and counterstained in hematoxylin
(Dako real hematoxylin, S2020) before they were dehy-
drated and mounted.
Scoring and immunohistochemical analysis
Prior to immunohistochemistry, endometriotic lesions
consisting of well-defined glandular epithelial and stromal
cells were identified in hematoxylin-eosin-stained sections
by a pathologist. Serial sections were cut from the chosen
samples. A semiquantitative subjective scoring system to
evaluate the localization, quantity and intensity of immu-
noreactivity was employed using light microscopy (200 ×
magnification). In each sample, the staining of glandular
epithelial cells and stromal cells was scored separately.
The intensity of the staining was scored using a four-point
scoring scale (0, negative staining; 1, weak staining; 2
moderate staining, 3, strong staining). The percentage of
positively stained cells was again scored using a four-point
scoring scale (0, negative staining; 1, 1-35 % positive cells;
2, 36-70 % positive cells; 3, >67 % positive cells). The two
scores were combined by multiplication to derive a final
IHC score (0–9). For epithelial or stromal TWIST1 and
epithelial MYC expression, a final score of ≥4 was regarded
as positive, and for stromal MYC expression, a final score
of ≥3 was regarded as positive (Fig. 1). Evaluations were
performed by two blinded investigators. The outcomes ana-
lyzed by two experienced investigators showed statistical
significance for the same results. An automatic quantitative
analysis system was not robust/adequate for the analysis of
our probes and was therefore not used. Positive and negative
(without primary antibody) controls were run concurrently.
The MYC protein was expressed in the nucleus of the epi-
thelial and the stromal cells of eutopic and ectopic endomet-
rium. TWIST expression was observed in the cytoplasm
and the nucleus of epithelial and stromal cells. However, as
a transcription factor, activated TWIST exerts its main func-
tion in the nucleus. Thus, for both factors, only the nuclear
staining of epithelial and stromal cells was evaluated.
Statistical analysis
Data were analyzed using SPSS (17.0). For association ana-
lyses, chi-squared tests were used. Wilcoxon and Mann
Whitney U tests were used to compare the two groups.
For correlation analyses, Spearman tests were used. For
paired statistics, the McNemar Test and Wilcoxon Signed
Ranks Test were used. A linear regression model was
Fig. 1 Immunohistochemical staining of MYC and TWIST1 in eutopic and
ectopic endometrial tissue. Anti-MYC antibody was applied at a dilution
of 1:100 and yielded negative (a, b) or positive (c, d) nuclear staining in
eutopic (a, c) and ectopic (b, d) tissue. Anti-TWIST1 antibody was applied
at a dilution of 1:1200 and yielded cytoplasmatic and nuclear staining.
For evaluation, only nuclear staining was analyzed. Anti-TWIST1 antibody
yielded negative (e, f) or positive (g, h) nuclear staining in eutopic (e, g)
and ectopic (f, h) tissue. Magnification = 200x
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and cycle phase. We considered the subgroup analyses as
exploratory and hence did not adjust for multiple testing,
as recommended by Bender and Lange [34]. Statistical sig-
nificance was defined as p < 0.05.
Results
Decrease of CDH1 and increase of TWIST1, SNAIL and
SLUG occur concordantly in ectopic lesions
CDH1 mRNA expression was significantly decreased in ec-
topic lesions compared to the eutopic gland epithelium of
controls and patients in unpaired (both p < 0.001; Mann
Whitney U Test, Fig. 2a) and paired samples (p < 0.001,
McNemar Test, Table 1). In contrast, TWIST1 expression
was significantly increased in ectopic lesions compared to
eutopic gland epithelium of controls and patients in un-
paired (p < 0.001 and p = 0.026; Mann Whitney U Test,
Fig. 2b) and paired samples (p = 0.049, McNemar Test,
Table 1). TWIST1 was also significantly more highly
expressed in the eutopic endometrium of patients than in
controls (p < 0.001; Mann Whitney U Test, Fig. 2b). In ec-
topic samples, most of the CDH1-negative samples (63.3 %)
were concordantly positive for TWIST1 expression (p < 0.001;McNemar Test, Table 2). In eutopic samples of controls and
patients, many of the CDH1-positive samples were concor-
dantly negative for TWIST1 expression (64.3 % of controls
and 48.5 % of patients, p < 0.001 and p = 0.012; McNemar
Test, Table 2). In conclusion, TWIST1 was upregulated,
whereas CDH1 was downregulated in ectopic tissues.
SNAIL expression was significantly increased in ectopic le-
sions compared to the eutopic gland epithelium of controls
and patients in unpaired (p = 0.016 and p = 0.013; Mann
Whitney U Test, Fig. 2c) and paired samples (p = 0.180,
McNemar Test, Table 1). In ectopic samples, most of the
CDH1-negative samples (52.08 %) were concordantly posi-
tive for TWIST1 expression (p < 0.001; McNemar Test,
Table 3). In eutopic samples of patients, many of the CDH1-
positive samples were concordantly negative for SNAIL ex-
pression (57.58 % of patients, p = 0.001; McNemar Test,
Table 3). The expression of TWIST1 correlates positively
with SNAIL expression in most samples (see Additional file
3: Table S4). In conclusion, SNAIL was upregulated whereas
CDH1 was downregulated in ectopic tissues.
Similar to TWIST1 and SNAIL expression, SLUG ex-
pression was significantly increased in ectopic lesions
compared to the eutopic gland epithelium of controls and
patients in unpaired (both p < 0.001; Mann Whitney U
Test, Fig. 2d) and paired samples (p = 0.007, McNemar
Test, Table 1). In ectopic samples, most of the CDH1-
negative samples (68.75 %) were concordantly positive for
SLUG expression (p < 0.001; McNemar Test, Table 4). In
eutopic samples of patients, many of the CDH1-positive
samples were concordantly negative for SLUG expression
(63.64 % of patients, p < 0.001; McNemar Test, Table 4).
In ectopic tissue, the expression of TWIST1 correlates
with SLUG expression (Additional file 4: Table S5). In
conclusion, SLUG was upregulated whereas CDH1 was
downregulated in ectopic tissues.
Increased TWIST1 and MYC in ectopic lesions
Epithelial TWIST1 expression was significantly more fre-
quent in ectopic lesions compared to eutopic gland epithe-
lium in unpaired (13.0 % vs. 47.7 %, p < 0.001; Chi2 Test,
Fig. 3a) and paired samples (p < 0.001, McNemar Test,
Table 5). Epithelial MYC expression was also more frequent
in ectopic endometriotic lesions than in eutopic gland epi-
thelium in unpaired samples (48.0 % vs. 71.8 %, p = 0.008,
Chi2 Test, Fig. 3b). However, in paired analysis, no signifi-
cant upregulation of MYC in ectopic samples was demon-
strated (p = 0.180). In stromal cells, TWIST1 was not
significantly differently expressed between eutopic and ec-
topic samples (Fig. 3a). In contrast, stromal MYC was
expressed in only 15.5 % of the ectopic lesions, while more
than 54 % of the eutopic endometrium samples showed
positive stromal MYC staining (p < 0.001, Chi2 Test, Fig. 3b).
Similarly, in paired analysis, stromal MYC expression was
significantly enhanced in eutopic samples compared to the
Fig. 2 Bar graph of relative expression levels of CDH1, TWIST1, SNAIL and SLUG. Expression levels of CDH1 mRNA (a) and TWIST1 mRNA (b) are
shown for controls (n = 45 and 47 for CDH1 and TWIST1, respectively) and eutopic (n = 42) and ectopic endometrial samples (n = 62). Expression
levels of SNAIL mRNA (c) and SLUG mRNA (d) are shown for controls (n = 47) and eutopic (n = 42) and ectopic endometrial samples (n = 62).
Expression levels were normalized to ß-actin and GAPDH. All p-values were analyzed by Mann–Whitney U Tests
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MYC positivity in eutopic samples and concordantly exhib-
ited MYC negativity in ectopic samples of the same patient
(p = 0.006, McNemar Test, Table 5). In conclusion, protein
expression of MYC and TWIST1 was upregulated in glan-
dular epithelium, whereas stromal MYC expression was
downregulated in ectopic tissues.
TWIST1 and MYC are not concurrently expressed
Next we analyzed the concurrent expression of TWIST1
and MYC in eutopic and ectopic tissues. Most eutopic
samples showing positive epithelial expression of MYCshowed negative epithelial staining for TWIST1 (83.3 %,
p = 0.002; McNemar test, Table 6). Similarly, in ectopic
lesions, 62.5 % of samples with positive epithelial
MYC staining showed MYC-negative epithelial cells
(p = 0.003, McNemar test, Table 6). In stromal cells of
ectopic tissues, 50.9 % of the samples with positive
TWIST1 expression showed negative MYC expression
(p < 0.001, McNemar test, Table 6). In conclusion,
TWIST and MYC were not expressed concurrently in
either eutopic endometrium or in ectopic lesions. It
appears that the expression of one gene excludes the
expression of the other.
Table 1 CDH1, TWIST1, SNAIL and SLUG expressions in the
eutopic and ectopic endometrium of the same patient
Ectopic CDH1
total neg pos p-value
Eutopic CDH1 neg 7 4 (57.1 %) 3 (42.9 %) 0.001
pos 22 18 (81.8 %) 4 (18.2 %)
Ectopic TWIST1
total neg pos p-value
Eutopic TWIST1 neg 15 2 (13.3 %) 13 (86.7 %) 0.049
pos 14 4 (28.6 %) 10 (71.4 %)
Ectopic SNAIL
total neg pos p-value
Eutopic SNAIL neg 17 7 (41.2 %) 10 (58.8 %) 0.180
pos 12 4 (33.3 %) 8 (66.7 %)
Ectopic SLUG
total neg pos p-value
Eutopic SLUG neg 20 7 (35 %) 13 (65 %) 0.007
pos 9 2 (22.2 %) 7 (77.8 %)
Numbers of patients in each of the indicated subgroups are shown. Numbers
in parentheses indicate the fraction of patients (%) in each row in ectopic
endometriotic lesions negative and positive for CDH1, TWIST1, SNAIL or SLUG.
All p-values of subgroup comparisons were analyzed by the McNemar Test
Table 3 Correlation of CDH1 and SNAIL expressions in control,
eutopic and ectopic samples
Controls
SNAIL
total neg pos p-value
CDH1 neg 19 14 (73.7 %) 5 (36.3 %) 0.210
pos 28 11 (39.3 %) 17 (60.7 %)
Eutopic
SNAIL
total neg pos p-value
CDH1 neg 9 6 (66.7 %) 3 (33.3 %) 0.001
pos 33 19 (57.6 %) 14 (42.4 %)
Ectopic
SNAIL
total neg pos p-value
CDH1 neg 48 23 (47.9 %) 25 (52.1 %) <0.001
pos 14 2 (14.3 %) 12 (85.7 %)
Numbers of patients in each of the indicated subgroups are shown. Numbers
in parentheses indicate the fraction of patients (%) in each row negative and
positive for SNAIL. All p-values of subgroup comparisons were analyzed by the
McNemar Test
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It is known that nuclear MYC expression is upregulated
during the proliferative phase of the menstrual cycle
[35, 26, 36]. Accordingly, in the eutopic endometrium of
endometriosis patients, epithelial MYC expression isTable 2 Correlation of CDH1 and TWIST1 expressions in control,
eutopic and ectopic samples
Controls
TWIST1
total neg pos p-value
CDH1 neg 17 17 (100 %) 0 (0.0 %) <0.001
pos 28 18 (64.3 %) 10 (35.7 %)
Eutopic
TWIST1
total neg pos p-value
CDH1 neg 9 5 (55.6 %) 4 (44.4 %) 0.012
pos 33 16 (48.5 %) 17 (51.5 %)
Ectopic
TWIST1
total neg pos p-value
CDH1 neg 49 18 (36.7 %) 31 (63.3 %) <0.001
pos 13 0 (0.0 %) 13 (100 %)
Numbers of patients in each of the indicated subgroups are shown. Numbers
in parentheses indicate the fraction of patients (%) in each row negative and
positive for TWIST. All p-values of subgroup comparisons were analyzed by the
McNemar Testobserved more frequently in patients in the proliferative
cycle phase than in the secretory phase (p < 0.001, Chi2
test, see Additional file 5: Table S4). In endometriotic le-
sions, epithelial MYC expression is associated with the
proliferative cycle phase, while negative MYC is signifi-
cantly associated with the secretory phase of the patientsTable 4 Correlation of CDH1 and SLUG expressions in control,
eutopic and ectopic samples
Controls
SLUG
total neg pos p-value
CDH1 neg 19 15 (79.0 %) 4 (21.1 %) 0.019
pos 28 15 (53.6 %) 13 (46.4 %)
Eutopic
SLUG
total neg pos p-value
CDH1 neg 9 7 (77.9 %) 2 (22.2 %) <0.001
pos 33 21 (63.6 %) 12 (36.4 %)
Ectopic
SLUG
total neg pos p-value
CDH1 neg 48 15 (31.3 %) 33 (68.8 %) <0.001
pos 14 2 (14.3 %) 12 (85.7 %)
Numbers of patients in each of the indicated subgroups are shown. Numbers
in parentheses indicate the fraction of patients (%) in each row negative and
positive for SLUG. All p-values of subgroup comparisons were analyzed by the
McNemar Test
Fig. 3 Expression and localization of TWIST1 and MYC in eutopic and ectopic endometrial tissue. IHC was used to analyze the protein expression
of TWIST1 (a) and MYC (b). Results are expressed as the percentage of positively stained samples in eutopic (n = 69 and 50 for TWIST1 and MYC,
respectively) and ectopic samples (n = 86 and 71 for TWIST1 and MYC, respectively). Epithelial and stromal expression was analyzed separately. All
p-values of subgroup comparisons were analyzed by chi-squared tests
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regression model with epithelial MYC expression as the
dependent variable and cycle phase and epithelial TWIST
expression as independent variables, only cycle phase
remained as an independent factor influencing epithelial
MYC expression (p = 1.11×10−6, Coefficient −0.413, data
not shown). No significant correlation was observed be-
tween the stromal MYC expression and the cycle phase of
the patients in either eutopic or ectopic endometrium (see
Additional file 5: Table S4). TWIST1 and CDH1 expres-
sion did not correlate with the cycle phase in eutopic and
in ectopic tissue (see Additional file 5: Table S3). In con-
clusion, a positive correlation between expression and
menstrual cycle phase was found for epithelial MYC only.
CDH1, TWIST1 and MYC expression did not correl-
ate with the rAFS staging classification (data not shown).
When gene expression was analyzed according to the
type of lesion (ie, ovarian, peritoneal, DIE), a significant
difference was only found for the median TWISTTable 5 Epithelial and stromal TWIST1 and MYC expressions in the e
Ectopic TWIST1
total neg
Eutopic Epithelial TWIST1 neg 42 15
pos 5 3




Eutopic Epithelial MYC neg 14 7
pos 15 2
Eutopic Stromal MYC neg 15 14
pos 14 11
Numbers of patients in each of the indicated subgroups are shown. Numbers in pa
endometriotic lesions negative and positive for TWIST or MYC. All p-values of subgrexpression between ovarian and DIE lesions (median
0.087 vs 0.059, p = 0.003).
Discussion
In the present study, we were able to demonstrate that
epithelial TWIST1, SNAIL and SLUG expression was
overexpressed in ectopic lesions compared to eutopic
endometrium glands. Correspondingly, in paired analysis
of samples from the same patient, we found that in a sig-
nificant proportion of samples, TWIST1, SNAIL and
SLUG expression was negative in eutopic endometrium,
whereas it was positive in ectopic lesions. We further
showed overexpression of MYC in the glandular epithe-
lium of endometriotic lesions compared to eutopic endo-
metrium. Analysis of matched tissue samples revealed a
trend towards more frequent epithelial MYC expression
in ectopic lesions, although this did not reach significance.
Few data exist that indicate a potential role of TWIST1 in
the pathogenesis of endometriosis [14, 37]. Moreover, weutopic and ectopic endometrium of the same patient
pos p-value
(35.7 %) 27 (64.3 %) <0.001
(60.0 %) 2 (40.0 %)
(52.6 %) 9 (47.4 %) 0.664
(42.9 %) 16 (57.1 %)
pos p-value
(50,0 %) 7 (50,0 %) 0.180
(13.3 %) 13 (86.7 %)
(93.3 %) 1 (6.7 %) 0.006
(78.6 %) 3 (21.4 %)
rentheses indicate the fraction of patients (%) in each row in ectopic
oup comparisons were analyzed by the McNemar Test
Table 6 Correlation of epithelial and stromal TWIST1 and MYC
expressions in eutopic and ectopic samples
Eutopic endometrium
TWIST1
total neg pos p-value
Epithelial MYC neg 26 22 (84.6 %) 4 (15.4 %) 0.002
pos 24 20 (83.3 %) 4 (16.7 %)
Stromal MYC neg 23 9 (39.1 %) 14 (60.9 %) 0.115
pos 27 6 (22.2 %) 21 (77.8 %)
Ectopic lesions
TWIST1
total neg pos p-value
Epithelial MYC neg 20 10 (50.0 %) 10 (50.0 %) 0.003
pos 48 30 (62.5 %) 18 (37.5 %)
Stromal MYC neg 57 28 (49.1 %) 29 (50.9 %) <0.001
pos 11 5 (45.5 %) 6 (54.5 %)
Numbers of patients in each of the indicated subgroups are shown. Numbers
in parentheses indicate the fraction of patients (%) in each row negative and
positive for TWIST1. All p-values of subgroup comparisons were analyzed by
the McNemar Test
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and CDH1 in controls and eutopic and ectopic tissue of
patients. In addition, a significant inverse expression be-
tween SNAIL/ SLUG and CDH1 was observed in eutopic
and ectopic tissue of patients. This finding suggests that
TWIST1, SNAIL and SLUG might be important regula-
tors of EMT in endometrium that is obviously upregu-
lated in ectopic lesions. A study including patients with
ovarian endometriosis analyzed mRNA expression of the
stemness-related gene OCT4 and TWIST1 [37]. They re-
ported an increased expression of OCT4 in ectopic endo-
metrium and a positive correlation of OCT4 with
TWIST1 [37]. The study that measured the mRNA ex-
pression of homogenized cells lacked discrimination be-
tween stromal and epithelial tissue. In our study of 110
endometriosis patients, we discriminated between epithe-
lial and stromal protein expression by using IHC analysis
for TWIST1 and MYC. We found that the epithelial ex-
pression of TWIST1 is significantly increased in ectopic
endometrium while the stromal expression is reduced.
Our findings suggest that the enhanced expression of
TWIST1, SNAIL and SLUG in ectopic lesions plays a cru-
cial role in the formation and maintenance of ectopic le-
sions in endometriosis. It can be hypothesized that the
glandular epithelial cells lose polarity and cell-to-cell con-
tacts by EMT and acquire migratory and invasive abilities
to establish ectopic lesions.
In endometriosis, EMT is induced by multiple signals.
For example, 17ß-estradiol (E2), which is known to be
high in endometriotic tissue, has been shown to induce
EMT in human endometrial epithelial cells through up-
regulation of the hepatocyte growth factor [38–40]. EMTcan be induced by proinflammatory cytokines. One inflam-
matory mediator relevant in EMT is TGF-ß which is in-
creased in peritoneal fluid of women with endometriosis
[41]. TNF-α and IL-6 may synergistically nudge the TGF-ß
signaling pathway towards EMT progression [42]. A signifi-
cantly increased secretion of TNF-α and IL-6 in the culture
media of peritoneal macrophages of endometriosis patients
was found in response to E2 compared to nontreated mac-
rophages [39]. Moreover, levels of IL-6 are higher in human
endometrial stromal cells derived from the endometrial bi-
opsies of women with endometriosis when compared with
women without the disease [43]. TNF-α and IL-6 but also
oxidative stress can promote NF-κB activation, which regu-
lates the expression of Snail1, Slug, Twist, ZEB1, and ZEB2
[44, 42]. A recent study showed that iron overload leads to
NF-κB activation in human endometrial stromal cells [44].
MYC is a well-known oncogene, and its function in
tumor formation has been intensively studied. In endo-
metriosis, the overexpression of MYC is also well estab-
lished. Nevertheless, the role in pathogenesis is still
unclear. MYC is upregulated in the ectopic and eutopic
endometrium of patients with endometriosis when analyzed
by reverse transcription PCR and IHC [26, 29–31, 25].
In the present study, we observed higher MYC ex-
pression in the glandular epithelium of endometriotic
lesions compared to eutopic tissues, in concordance with
Pellegrini et al. MYC overexpression suggests a higher
proliferation rate in lesions than in eutopic tissues. In
contrast to the epithelial expression of MYC, the stromal
expression of MYC was predominantly negative in the
ectopic endometrium.
Our observation of overexpressed MYC and TWIST1 in
the epithelial cells of ectopic lesions prompted us to investi-
gate a putative correlation of these two markers. In the
present study, we were not able to detect the concurrent
regulation of epithelial MYC and TWIST1 in the same
sample in either eutopic or ectopic tissues. Actually, the
exact opposite was true. We found a significant inverse ex-
pression of MYC and TWIST1 in paired samples. Thus, we
excluded a simultaneous upregulation of TWIST1 and
MYC that may orchestrate the cellular changes associated
with invasion and proliferation in endometriosis. It seems
that a high expression of TWIST1, which was shown to be
associated with the stemness marker OCT4 in endometri-
osis, excludes a high expression of MYC, which is associ-
ated with proliferation [37] in endometriosis. TWIST1 has
also been shown to be an important regulator of stemness
in epithelial ovarian cancer [45, 46]. Thus, in ectopic lesions
with high epithelial MYC expression, the additional upregu-
lation of TWIST1 appears to provide no further advantage
for the cell and vice versa. There are several other theories
concerning the pathogenesis of endometriosis. Some stud-
ies revealed the presence of adult stem cells in the basalis
but also functionalis layers of the human endometrium
Proestling et al. Reproductive Biology and Endocrinology  (2015) 13:75 Page 9 of 11[47–50]. These endometrium-derived stem cells, which
are distributed by retrograde menstrual efflux, may also
contribute to the establishment of ectopic endometriotic
lesions [50–54]. The monoclonal origin of some endome-
triotic lesions, long-time culture properties of cell clones
established from endometriotic lesions, and the isolation
of progenitor cells from menstrual blood support this
hypothesis [55–60]. Another theory concerning the patho-
genesis of endometriosis is the coelomic metaplasia the-
ory, which proposes that mesothelial cells on the ovary or
pelvis change to endometriotic gland cells [61, 62].
The observation of increased MYC expression during
the proliferative cycle phase has already been reported
[35, 26, 36]. In utero, MYC is upregulated by estrogens by
an estrogen response cis-acting element (ERE) in its pro-
motor [63–65]. Endometriotic lesions show increased pro-
duction of estradiol and higher concentrations of estradiol
have been detected in the peritoneal fluid of women with
endometriosis than in that of normal controls [66]. Com-
pared to estrogen receptor (ER) α, ERß is expressed in
markedly higher levels in ectopic lesions than in eutopic
tissue. [67]. Deficient methylation of the ERß gene promo-
tor has been suggested to result in pathological overex-
pression of ERß in endometriosis, which in turn represses
ERα expression [67]. Previous studies showed a remark-
ably elevation of ERß mRNA and protein expression rela-
tive to the normal endometrium [68, 25]. In addition, the
eutopic endometrium of women with endometriosis have
elevated ERß expression when compared with the endo-
metrium of healthy women [69–71], suggesting that high
levels of ERß in the endometrium may predispose women
to endometriosis. Increased MYC expression might be
due to enhanced local estrogen levels in endometriotic le-
sions [72, 63, 65]. In this study, we showed a significant
correlation between MYC expression and the proliferative
menstrual cycle phase of the women with high estrogen
levels. In contrast, we confirmed previous findings that
the expression of TWIST1 was not associated with cycle
phase [14].
Conclusions
We showed a significant inverse expression between
TWIST1 and CDH1 in controls and eutopic and ectopic
tissue of endometriosis patients. Furthermore, a significant
inverse expression between SNAIL/ SLUG and CDH1 was
observed in eutopic and ectopic tissue of patients. These
findings suggest that TWIST1, SNAIL and SLUG might
be important regulators of EMT in endometrium. More-
over, EMT seems to be enhanced in ectopic lesions com-
pared to eutopic tissue. The results reported herein show
increased expression of epithelial TWIST1 and MYC in
ectopic endometrium compared to eutopic endometrium
in paired and unpaired analysis. Although both were up-
regulated, TWIST1 and MYC were not expressedconcurrently, which suggest that in cells with high MYC
expression, an additional upregulation of TWIST1 and
vice versa seems to provide no further advantage for the
development of endometriosis. The transcription factor
TWIST1 and the oncogene MYC seem to contribute inde-
pendently of each other to the formation of endometriotic
lesions.
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